143 related articles for article (PubMed ID: 26577754)
1. Relationship between etonogestrel level and BMI in women using the contraceptive implant for more than 1 year.
Morrell KM; Cremers S; Westhoff CL; Davis AR
Contraception; 2016 Mar; 93(3):263-5. PubMed ID: 26577754
[TBL] [Abstract][Full Text] [Related]
2. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
McNicholas C; Swor E; Wan L; Peipert JF
Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
[TBL] [Abstract][Full Text] [Related]
3. Relationship between patient characteristics and serum etonogestrel concentrations in contraceptive implant users.
Lazorwitz A; Aquilante CL; Sheeder J; Guiahi M; Teal S
Contraception; 2019 Jul; 100(1):37-41. PubMed ID: 30980827
[TBL] [Abstract][Full Text] [Related]
4. The effect of carbamazepine on etonogestrel concentrations in contraceptive implant users.
Lazorwitz A; Davis A; Swartz M; Guiahi M
Contraception; 2017 Jun; 95(6):571-577. PubMed ID: 28288788
[TBL] [Abstract][Full Text] [Related]
5. Postpartum weight loss in overweight and obese women using the etonogestrel subdermal implant: a pilot study.
Griffin L; Hammond C; Liu D; Rademaker AW; Kiley J
Contraception; 2017 Jun; 95(6):564-570. PubMed ID: 28238839
[TBL] [Abstract][Full Text] [Related]
6. The effect of rifampin on serum etonogestrel concentrations and biomarkers of ovulation among contraceptive implant users: A pharmacokinetic and pharmacodynamic study.
Lazorwitz A; Sheeder J; Teal S
Contraception; 2023 Jul; 123():110035. PubMed ID: 36997081
[TBL] [Abstract][Full Text] [Related]
7. Assessing Weight Status in Adolescent and Young Adult Users of the Etonogestrel Contraceptive Implant.
Romano ME; Braun-Courville DK
J Pediatr Adolesc Gynecol; 2019 Aug; 32(4):409-414. PubMed ID: 30928532
[TBL] [Abstract][Full Text] [Related]
8. Pilot study of a novel, alternative subdermal scapular insertion site for the etonogestrel contraceptive implant.
Clure C; Sheeder J; Lazorwitz A
Contraception; 2024 Jul; 135():110442. PubMed ID: 38552822
[TBL] [Abstract][Full Text] [Related]
9. Bioequivalence and x-ray visibility of a radiopaque etonogestrel implant versus a non-radiopaque implant: a 3-year, randomized, double-blind study.
Schnabel P; Merki-Feld GS; Malvy A; Duijkers I; Mommers E; van den Heuvel MW
Clin Drug Investig; 2012 Jun; 32(6):413-22. PubMed ID: 22540269
[TBL] [Abstract][Full Text] [Related]
10. Contraceptive vaginal ring effectiveness is maintained during 6 weeks of use: a prospective study of normal BMI and obese women.
Dragoman M; Petrie K; Torgal A; Thomas T; Cremers S; Westhoff CL
Contraception; 2013 Apr; 87(4):432-6. PubMed ID: 23312933
[TBL] [Abstract][Full Text] [Related]
11. Relationship Between Etonogestrel Concentrations and Bleeding Patterns in Contraceptive Implant Users.
Lazorwitz A; Aquilante CL; Dindinger E; Harrison M; Sheeder J; Teal S
Obstet Gynecol; 2019 Oct; 134(4):807-813. PubMed ID: 31503152
[TBL] [Abstract][Full Text] [Related]
12. Impact of etonogestrel implant use on T-cell and cytokine profiles in the female genital tract and blood.
Haddad LB; Swaims-Kohlmeier A; Mehta CC; Haaland RE; Brown NL; Sheth AN; Chien H; Titanji K; Achilles SL; Lupo D; Hart CE; Ofotokun I
PLoS One; 2020; 15(3):e0230473. PubMed ID: 32214321
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen for the treatment of breakthrough bleeding with the etonogestrel implant: a randomized controlled trial.
Simmons KB; Edelman AB; Fu R; Jensen JT
Contraception; 2017 Feb; 95(2):198-204. PubMed ID: 27725164
[TBL] [Abstract][Full Text] [Related]
14. Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration-approved duration.
McNicholas C; Maddipati R; Zhao Q; Swor E; Peipert JF
Obstet Gynecol; 2015 Mar; 125(3):599-604. PubMed ID: 25730221
[TBL] [Abstract][Full Text] [Related]
15. A Comparison of Breastfeeding Exclusivity and Duration Rates Between Immediate Postpartum Levonorgestrel Versus Etonogestrel Implant Users: A Prospective Cohort Study.
Krashin JW; Lemani C; Nkambule J; Talama G; Chinula L; Flax VL; Stuebe AM; Tang JH
Breastfeed Med; 2019; 14(1):69-76. PubMed ID: 30508390
[TBL] [Abstract][Full Text] [Related]
16. Twelve-month Continuation of the Etonogestrel Implant in Adolescents With Polycystic Ovary Syndrome.
Buyers E; Sass AE; Severn CD; Pyle L; Cree-Green M
J Pediatr Adolesc Gynecol; 2021 Feb; 34(1):33-39. PubMed ID: 32919086
[TBL] [Abstract][Full Text] [Related]
17. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
[TBL] [Abstract][Full Text] [Related]
18. Comparison of plasma etonogestrel concentrations sampled from the contralateral-to-implant and ipsilateral-to-implant arms of contraceptive implant users.
Gertz AM; Bishop IJ; Simon B; Lechiile K; Badubi O; Mussa A; Westhoff CL; Morroni C
Contraception; 2020 Dec; 102(6):403-405. PubMed ID: 32858051
[TBL] [Abstract][Full Text] [Related]
19. Menstrual bleeding patterns in adolescents using etonogestrel (ENG) implant.
Deokar AM; Jackson W; Omar HA
Int J Adolesc Med Health; 2011; 23(1):75-7. PubMed ID: 21721368
[TBL] [Abstract][Full Text] [Related]
20. Immediate versus delayed insertion of an etonogestrel releasing implant at medical abortion-a randomized controlled equivalence trial.
Hognert H; Kopp Kallner H; Cameron S; Nyrelli C; Jawad I; Heller R; Aronsson A; Lindh I; Benson L; Gemzell-Danielsson K
Hum Reprod; 2016 Nov; 31(11):2484-2490. PubMed ID: 27664217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
